Should You Buy Intuitive Surgical With the Stock Down 35%? Here's What History Says.

The core issue is not whether the platform is structurally advantaged; it is whether the market is still willing to pay a scarcity multiple for growth that is normalizing. For ISRG, the recurring consumables/service stream should keep downside from becoming catastrophic, but that same annuity profile also makes the stock vulnerable to multiple compression when procedure growth decelerates even modestly. In other words, the business can stay healthy while the equity derates another turn or two.

The second-order dynamic is competitive rather than binary. A slowdown in new system installs tends to shift investor attention toward share gains in lower-cost or more flexible robotic offerings, which is where MDT can benefit if hospitals defer capex and demand more options leverage per OR dollar. Over 1-3 months, the key catalyst is any evidence that procedure growth is tracking closer to the lower end of guidance; over 6-18 months, the real test is whether the installed base still expands fast enough to offset a maturing replacement cycle.

Contrarianly, the consensus may be over-anchored to the historical pattern of drawdowns reversing, without accounting for how much of prior upside came from valuation expansion rather than fundamental acceleration. At ~47x earnings, ISRG is no longer priced like a deep-moat compounder with no competition; it is priced like a premium growth asset that needs clean execution every quarter. What would falsify the bearish case is sustained procedure growth re-acceleration and evidence that competition is failing to monetize installed-base economics; absent that, the stock can drift lower even if the operating story remains intact.